Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

This study has been terminated.
(Due to potential concerns about liver safety (See Detailed Description))
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01834274
First received: April 12, 2013
Last updated: August 26, 2015
Last verified: August 2015
Results First Received: March 27, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Fasiglifam (TAK-875)
Drug: Fasiglifam (TAK-875) Placebo
Drug: Sitagliptin
Drug: Sitagliptin Placebo
Drug: Metformin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants took part in the study at 25 sites in the United States and 1 site in Canada from 18 May 2013 (first patient to sign informed consent) to 05 March 2014.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants with a diagnosis of Type 2 Diabetes Mellitis were enrolled equally in 1 of 2 treatment groups, once a day fasiglifam 50 mg or Sitagliptin 100 mg in combination with metformin.

Reporting Groups
  Description
Fasiglifam 50 mg Fasiglifam 50 mg tablets, orally, once daily, sitagliptin placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
Sitagliptin 100 mg Sitagliptin 100 mg, tablets, once daily, fasiglifam placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum tolerated dose), tablets, orally, daily for up to 24 weeks.

Participant Flow:   Overall Study
    Fasiglifam 50 mg   Sitagliptin 100 mg
STARTED   50   46 
COMPLETED   3   5 
NOT COMPLETED   47   41 
Study Termination                41                38 
Withdrawal by Subject                1                1 
Lost to Follow-up                3                1 
Other                2                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All randomized participants.

Reporting Groups
  Description
Fasiglifam 50 mg Fasiglifam 50 mg tablets, orally, once daily, sitagliptin placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
Sitagliptin 100 mg Sitagliptin 100 mg, tablets, once daily, fasiglifam placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum tolerated dose), tablets, orally, daily for up to 24 weeks.
Total Total of all reporting groups

Baseline Measures
   Fasiglifam 50 mg   Sitagliptin 100 mg   Total 
Overall Participants Analyzed 
[Units: Participants]
 50   46   96 
Age 
[Units: Years]
Mean (Standard Deviation)
 57.6  (7.14)   55.1  (9.07)   56.4  (8.17) 
Age, Customized 
[Units: Participants]
     
< 65 years   41   41   82 
≥ 65 years   9   5   14 
Gender 
[Units: Participants]
     
Female   24   20   44 
Male   26   26   52 
Race/Ethnicity, Customized 
[Units: Participants]
     
Asian   2   1   3 
Black or African American   6   6   12 
Native Hawaiian or Other Pacific Islander   0   1   1 
White   42   37   79 
Multiracial   0   1   1 
Race/Ethnicity, Customized 
[Units: Participants]
     
Hispanic or Latino   34   31   65 
Non-Hispanic or Latino   15   15   30 
Not Available   1   0   1 
Region of Enrollment 
[Units: Participants]
     
Canada   1   0   1 
United States   49   46   95 
Height 
[Units: Cm]
Mean (Standard Deviation)
 168.7  (11.45)   169.9  (10.79)   169.3  (11.10) 
Weight 
[Units: Kg]
Mean (Standard Deviation)
 87.50  (18.769)   96.09  (19.295)   91.62  (19.408) 
Body Mass Index (BMI) 
[Units: Kg/m^2]
Mean (Standard Deviation)
 30.77  (6.112)   33.13  (4.787)   31.90  (5.614) 
Baseline BMI Category 
[Units: Participants]
     
< 30 kg/m^2   31   11   42 
≥ 30 kg/m^2   19   35   54 
Baseline Glycosylated Hemoglobin (HbA)1c Category 
[Units: Participants]
     
< 9%   27   28   55 
≥ 9 %   23   18   41 
Duration of Diabetes 
[Units: Years]
Mean (Standard Deviation)
 10.075  (6.530)   8.877  (5.942)   9.501  (6.252) 
Smoking Classification 
[Units: Participants]
     
Never smoked   38   29   67 
Current smoker   7   9   16 
Ex-smoker   5   8   13 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in Glycosylated Hemoglobin (HbA1c)   [ Time Frame: Baseline and Week 24 ]

2.  Secondary:   Percentage of Participants With HbA1c <7% at Week 24   [ Time Frame: Week 24 ]

3.  Secondary:   Change From Baseline in Fasting Plasma Glucose (FPG)   [ Time Frame: Baseline and Week 24 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Medical Director, Clinical Science
Organization: Takeda
phone: +1-877-825-3327
e-mail: trialdisclosures@takeda.com



Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT01834274     History of Changes
Other Study ID Numbers: TAK-875_310
2013-000542-19 ( EudraCT Number )
U1111-1139-0467 ( Registry Identifier: WHO UTN )
DOH-27-0913-4426 ( Registry Identifier: SANCTR (South Africa) )
NMRR-13-518-16346 ( Registry Identifier: NMRR (Malaysia) )
PHRR140127-000165 ( Registry Identifier: PHRR (Philippines) )
Study First Received: April 12, 2013
Results First Received: March 27, 2015
Last Updated: August 26, 2015